Coronary Heart Disease and Fish Oil
Talya Spivack, MD

Introduction
The benefits of fish consumption on cardiovascular disease has been suggested since the early 1980s in studies that demonstrated Greenland Eskimo’s low rates of death from coronary heart disease. This was followed by another observational study that demonstrated the same findings in Japan. The proposed linkage between these two groups of people is their propensity to consume fish. Since then many studies have examined the relationship between fish consumption and coronary heart disease (CHD) mortality rates. Current thinking suggests that the primary benefit of consuming fish is secondary to the omega-3 fatty acids found in fish oil.

Omega-3 Fatty Acid Sources and Action
Omega-3 fatty acids are long-chain polyunsaturated fatty acids (18-22 carbon atoms in chain length) with the first of double bonds beginning with the third carbon atom. Plants and marine fish are the two main dietary sources of omega-3 fatty acids found in nature. For the purposes of this article, we will mainly discuss the role of marine omega-3 fatty acids. These are generally found in oily fish such as mackerel, lake trout, herring, sardines, albacore tuna and salmon. There are two types of marine omega-3 fatty acids: eicosapentaenoic acid (EPA) & docosahexanoic acid (DHA). In the human body, these are broken down by the enzymes cyclo-oxygenase and then lipoxigenase to create eicosanoids.

The exact mechanism of action of omega-3 fatty acids on CHD remains unknown. However, several ideas have been postulated. Omega-3 fatty acids have been shown to decrease serum triglyceride concentrations in a dose dependent relationship by 25-30%. Omega-3 fatty acids have also been linked to decreased platelet aggregation as well as the ability to stabilize the myocardium against ventricular arrhythmia in animal studies.

The Evidence
One of the first significant prospective trials done demonstrating the correlation between consumption of omega-3 fatty acids and coronary heart disease was done in the Netherlands over a 20 year period. Information about the fish consumption of 852 middle-aged men without coronary heart disease was collected by a careful dietary history obtained from the participants and their wives. During 20 years of follow-up 78 men died from coronary heart disease. An inverse dose-response relation was observed between fish consumption in 1960 and death from coronary heart disease during 20 years of follow-up. Mortality from coronary heart disease was more than 50% lower among those who consumed at least 30 grams of fish per day than among those who did not eat fish. It was concluded that the consumption of as little as one or two fish dishes per week may be of preventive value in relation to coronary heart disease.

The Netherlands study was shortly followed by the Diet and Reinfarction Trial (DART) of 1989. This was a randomized control trial with factorial design performed with the intent to examine the effect of dietary intervention in secondary prevention of MI. The major endpoints of the study were total mortality and ischemic heart disease events (IHD events and nonfatal MI). Men enrolled in the trial were weighed, measured, and randomly assigned to receive or not receive dietary advice on three factors. The first factor was total fat intake. The men in this arm were designated to reduce fat intake to 30% of total energy and to increase the polyunsaturated/saturated fat ratio as much as possible. The next arm was the fish arm. Men were told to consume at least two weekly portions (200-400 g) of fatty fish (mackerel, herring, kipper, pilchard, sardine, salmon, and trout). Men who could not tolerate fish were given the option of taking three fish oil capsules per day, providing a total of 900 mg EPA and DHA. The next arm of the study examined fiber intake. These men were instructed to increase their intake of cereal fiber to 18 g daily. Weight reduction advice and smoking advice were given as seen fit to all arms of the study. The results were surprising. The fish oil arm was shown to have the most CHD benefit demonstrated by an overall reduction of cardiovascular disease mortality by 29%. Surprisingly, the overall dietary fat group did demonstrate a significant decrease in the number of MIs suffered but did not show any overall benefit in mortality.

The next large randomized control study to demonstrate a similar benefit was The Indian Experiment of Infarct Survival published in 1997. This randomized placebo controlled trial aimed to test the effect of fish oil and mustard oil supplementation versus placebo on complications and cardiac events in patients with prior suspected acute myocardial infarction during a follow-up period of 1 year after symptoms were first experienced. Participants were randomized to fish oil (6 capsules per day, providing approximately 2 g of omega-3 fatty acids), mustard seed oil (a source of a-linolenic acid, 2.9 g/d provided in 20 mL of oil), and placebo (aluminum hydroxide, 100 mg). After one year, total cardiac events were 25% and 28% in the fish oil and mustard oil groups, respectively, versus 35% in the placebo group. The success of the DART trial and the Indian Experiment of Infarct Survival trial spawned the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico (GISSI) trial in 1999. This trial was a secondary prevention clinical trial designed to assess the effects of omega-3 polyunsaturated fatty acid and vitamin E supplementation on mortality and recurrent events in patients with recent MI. The study randomized 11,324 patients to receive either fish oil (6 capsules per day, providing approximately 3 g of omega-3 fatty acids), vitamin E (400 mg/day), both, or neither. In 1999, the GISSI-2 trial demonstrated a significant reduction in mortality, recurrent MI and stroke in patients who received fish oil compared to those who received vitamin E alone or neither of these supplements. In 2002, a larger GISSI-Prevenzione trial confirmed these results in a trial of 11,324 patients who were randomized to receive fish oil (6 capsules per day, providing approximately 4 g of omega-3 fatty acids), vitamin E (400 mg/day), both, or neither. The Fish Oil and Omega 3marCerIdation in inEndine (FOCE) was another large randomized control trial that demonstrated the benefit of omega-3 fatty acids on cardiovascular disease.

The Evidence
One of the first significant prospective trials done demonstrating the correlation between consumption of omega-3 fatty acids and coronary heart disease was done in the Netherlands over a 20 year period. Information about the fish consumption of 852 middle-aged men without coronary heart disease was collected by a careful dietary history obtained from the participants and their wives. During 20 years of follow-up 78 men died from coronary heart disease. An inverse dose-response relation was observed between fish consumption in 1960 and death from coronary heart disease during 20 years of follow-up. Mortality from coronary heart disease was more than 50% lower among those who consumed at least 30 grams of fish per day than among those who did not eat fish. It was concluded that the consumption of as little as one or two fish dishes per week may be of preventive value in relation to coronary heart disease.

The Netherlands study was shortly followed by the Diet and Reinfarction Trial (DART) of 1989. This was a randomized control trial with factorial design performed with the intent to examine the effect of dietary intervention in secondary prevention of MI. The major endpoints of the study were total mortality and ischemic heart disease events (IHD events and nonfatal MI). Men enrolled in the trial were weighed, measured, and randomly assigned to receive or not receive dietary advice on three factors. The first factor was total fat intake. The men in this arm were designated to reduce fat intake to 30% of total energy and to increase the polyunsaturated/saturated fat ratio as much as possible. The next arm was the fish arm. Men were told to consume at least two weekly portions (200-400 g) of fatty fish (mackerel, herring, kipper, pilchard, sardine, salmon, and trout). Men who could not tolerate fish were given the option of taking three fish oil capsules per day, providing a total of 900 mg EPA and DHA. The next arm of the study examined fiber intake. These men were instructed to increase their intake of cereal fiber to 18 g daily. Weight reduction advice and smoking advice were given as seen fit to all arms of the study. The results were surprising. The fish oil arm was shown to have the most CHD benefit demonstrated by an overall reduction of cardiovascular disease mortality by 29%. Surprisingly, the overall dietary fat group did demonstrate a significant decrease in the number of MIs suffered but did not show any overall benefit in mortality.

The next large randomized control study to demonstrate a similar benefit was The Indian Experiment of Infarct Survival published in 1997. This randomized placebo controlled trial aimed to test the effect of fish oil and mustard oil supplementation versus placebo on complications and cardiac events in patients with prior suspected acute myocardial infarction during a follow-up period of 1 year after symptoms were first experienced. Participants were randomized to fish oil (6 capsules per day, providing approximately 2 g of omega-3 fatty acids), mustard seed oil (a source of a-linolenic acid, 2.9 g/d provided in 20 mL of oil), and placebo (aluminum hydroxide, 100 mg). After one year, total cardiac events were 25% and 28% in the fish oil and mustard oil groups, respectively, versus 35% in the placebo group.

The success of the DART trial and the Indian Experiment of Infarct Survival trial spawned the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico (GISSI) trial in 1999. This trial was a secondary prevention clinical trial designed to assess the effects of omega-3 polyunsaturated fatty acid and vitamin E supplementation on mortality and recurrent events in patients with recent MI. The study randomized 11,324 patients to receive either fish oil (6 capsules per day, providing approximately 3 g of omega-3 fatty acids), vitamin E (400 mg/day), both, or neither. In 1999, the GISSI-2 trial demonstrated a significant reduction in mortality, recurrent MI and stroke in patients who received fish oil compared to those who received vitamin E alone or neither of these supplements. In 2002, a larger GISSI-Prevenzione trial confirmed these results in a trial of 11,324 patients who were randomized to receive fish oil (6 capsules per day, providing approximately 4 g of omega-3 fatty acids), vitamin E (400 mg/day), both, or neither. The Fish Oil and Omega 3marCerIdation in inEndine (FOCE) was another large randomized control trial that demonstrated the benefit of omega-3 fatty acids on cardiovascular disease.
patients who had survived a myocardial infarction within the last 3 months to four arms: omega-3 fatty acid group received one capsule per day of a highly concentrated product containing about 850 mg of EPA and DHA, the vitamin-E group received 300 mg/d of synthetic a-tocopherol, the combined treatment group received both, and the control group received neither. The GISSI trial was the first demonstration that a pharmaceutical preparation of omega-3 fatty acids in addition to dietary and other accepted interventions has a favorable effect on clinical endpoints in post-MI patients. Another unexpected finding was those taking the omega-3 fatty acids experienced a 20% reduction in overall mortality and a 45% decrease in risk for sudden cardiac death.7,8

One of the confounders of the above randomized control trials was that the trials had only included men. As a result, a retrospective analysis relating coronary artery disease and fish oil was performed on the cohort of female patients used for the Nurse’s Health Study. The end point for this study was incidence of CHD including CHD deaths and nonfatal MI. Women were divided into 5 categories based on frequency of fish consumption: <1 serving per month, 1-3 servings per month, 1 serving per week, 2-4 servings per week, and 5 servings per week. This trial showed a steep decrease in all arms related to more fish consumption in total coronary heart disease cases, fatal coronary heart disease events, and nonfatal MI.9 Although this study is convincing, it is also limited by the inability to control for the fact that people who consume more fish products may have an inherently healthier lifestyle.

Conclusions
The physician must weigh the risks and benefits of prescribing fish oil to their patients. It is important to realize the antiplatelet effects and theoretical ramifications in using omega-3 fatty acids therapeutically in patients with bleeding tendencies. In addition, pregnant and nursing woman must be cautioned against consuming certain fish such as shark, swordfish, golden bass, and king mackerel that have a higher proportion of mercury. Studies suggest that prenatal mercury exposure can be detrimental to neurological development in children.10,19

In 2002, the American Heart Association (AHA) published guidelines advocating the use of omega-3 fatty acids in patients with and without documented CHD. In patients without CHD they recommended eating a variety of (preferably oily) fish at least twice a week. In patients with CHD they recommended consuming approximately 1 gram of EPA and DHA daily, preferably from oily fish. In addition they suggested that in this patient population fish oil capsules could be considered in consultation with physicians. In the patients needing triglyceride lowering the AHA recommended 2–4 grams of EPA and DHA daily provided as capsules under a physicians care.5

Omega 3 fatty acids have been shown in epidemiological studies and randomized control studies to decrease the incidence of coronary heart disease both in patients with existing coronary heart disease and prospectively. Although more studies are needed to examine the exact mechanism of action of omega-3 fatty acids, studies do show a substantial benefit related to the increase of intake of fish oil, both in capsule form and through dietary sources. In conclusion, evidence suggests recommending omega-3 fatty acids to patients at risk for and who have suffered from cardiovascular heart disease.

References
6. Penny M. Kris-Etherton, William S. Harris, Lawrence J. Appel and for the Nutrition Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease. Circulation 2002;106:2474-2577